HEMP AGRIMONY

OTHER NAME(S):

Alpenkraut, Cañamazo, Cáñamo Acuático, Cannabine, Chanvre d’Eau, Chanvrin, Donnerkraut, Dostenkraut, Drachenkraut, Dutch Agrimony, Dutch Eupatoire Commune, Eupatoire des Arabes, Eupatoire d’Avicenne, Eupatoire Chanvrine, Eupatoire à Feuilles de Chanvre, Eupatorio, Eupatorium cannabinum, Gemeiner Wasswedost, Herbe de Sainte Cunégonde, Hirshklee, Holy Rope, Kunigundendraut, Leberkraut, Origan des Marais, St. John's Herb, Sweet Mandulin, Sweet-Smelling Trefoil, Thoroughwort, Wasshanf, Waterhemp, Water Maudlin.<br/><br/>

Overview

Overview Information

Hemp agrimony is an herb. The flowering parts of the plant are used to make medicine.

Despite serious safety concerns, hemp agrimony is used for liver and gallbladder disorders, colds, and fever.

Some people apply hemp agrimony directly to the skin for wounds and skin infections.

How does it work?

There isn't enough information available to know how hemp agrimony works.

Uses

Uses & Effectiveness?

Insufficient Evidence for

  • Liver disorders.
  • Gallbladder disorders.
  • Colds.
  • Fever.
  • Other conditions.
More evidence is needed to rate the effectiveness of hemp agrimony for these uses.

Side Effects

Side Effects & Safety

There’s a lot of concern about using hemp agrimony as medicine, because it contains chemicals called hepatotoxic pyrrolizidine alkaloids (PAs), which may block blood flow in the veins and cause liver damage. Hepatotoxic PAs might also cause cancer and birth defects. Hemp agrimony preparations that are not certified and labeled “hepatotoxic PA-free” are considered UNSAFE.

It’s also UNSAFE to apply hemp agrimony to broken skin. The dangerous chemicals in hemp agrimony can be absorbed quickly through broken skin and can lead to dangerous body-wide toxicity. Steer clear of skin products that aren’t certified and labeled “hepatotoxic PA-free.”

There isn’t enough information to know if it’s safe to apply hemp agrimony to unbroken skin. It’s best to avoid use.

Special Precautions & Warnings:

Pregnancy and breast-feeding: It’s UNSAFE to use hemp agrimony preparations that might contain hepatotoxic PAs during pregnancy. These products might cause birth defects and liver damage.

It’s also UNSAFE to use hemp agrimony preparations that might contain hepatotoxic PAs if you are breast-feeding. These chemicals can pass into breast-milk and might harm the nursing infant.

It’s not known whether products that are certified hepatotoxic PA-free are safe to use during pregnancy or breast-feeding. Stay in the safe side and avoid using any hemp agrimony preparation if you are pregnant or breast-feeding.

Allergy to ragweed and related plants: Hemp agrimony may cause an allergic reaction in people who are allergic to the Asteraceae/Compositae plant family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many others. If you have allergies, be sure to check with your healthcare provider before taking hemp agrimony.

Liver disease: There is concern that the hepatotoxic PAs in hemp agrimony might make liver disease worse.

Interactions

Interactions?

Moderate Interaction

Be cautious with this combination

!
  • Medications that increase break down of other medications by the liver (Cytochrome P450 3A4 (CYP3A4) inducers) interacts with HEMP AGRIMONY

    Hemp agrimony is broken down by the liver. Some chemicals that form when the liver breaks down hemp agrimony can be harmful. Medications that cause the liver to break down hemp agrimony might enhance the toxic effects of chemicals contained in hemp agrimony.<br/><br/> Some of these medicines include carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), and others.

Dosing

Dosing

The appropriate dose of hemp agrimony depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for hemp agrimony. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References

REFERENCES:

  • Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol 2003;39:437-46. View abstract.
  • Food and Drug Administration. FDA Advises Dietary Supplement Manufacturers to Remove Comfrey Products From the Market. July 6, 2001. Available at: http://www.cfsan.fda.gov/~dms/dspltr06.html.
  • Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999;56:125-38. View abstract.
  • Roeder E. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie 1995;50:83-98.
  • Wang YP, Yan J, Fu PP, Chou MW. Human liver microsomal reduction of pyrrolizidine alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid. Toxicol Lett 2005;155:411-20. View abstract.
  • WHO working group. Pyrrolizidine alkaloids. Environmental Health Criteria, 80. WHO: Geneva, 1988.

More Resources for HEMP AGRIMONY

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version. © Therapeutic Research Faculty 2009.